NDC 55566-1010

Fyremadel

Ganirelix Acetate

Fyremadel is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Ferring Pharmaceuticals Inc.. The primary component is Ganirelix Acetate.

Product ID55566-1010_4f2833c9-d086-43c5-83d3-17d9986a7a3e
NDC55566-1010
Product TypeHuman Prescription Drug
Proprietary NameFyremadel
Generic NameGanirelix Acetate
Dosage FormInjection, Solution
Route of AdministrationSUBCUTANEOUS
Marketing Start Date2021-12-14
Marketing CategoryANDA /
Application NumberANDA204246
Labeler NameFerring Pharmaceuticals Inc.
Substance NameGANIRELIX ACETATE
Active Ingredient Strength250 ug/.5mL
Pharm ClassesDecreased GnRH Secretion [PE],Gonadotropin Releasing Hormone Receptor Antagonist [EPC],Gonadotropin Releasing Hormone Receptor Antagonists [MoA]
NDC Exclude FlagN
Listing Certified Through2022-12-31

Packaging

NDC 55566-1010-1

1 BLISTER PACK in 1 CARTON (55566-1010-1) > 1 SYRINGE in 1 BLISTER PACK > .5 mL in 1 SYRINGE
Marketing Start Date2021-12-14
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "Fyremadel" or generic name "Ganirelix Acetate"

NDCBrand NameGeneric Name
55566-1010Fyremadelganirelix acetate
0052-0301Ganirelix AcetateGanirelix Acetate
0548-5001Ganirelix AcetateGanirelix Acetate
55566-1000Ganirelix AcetateGanirelix Acetate
62756-072Ganirelix AcetateGanirelix Acetate
71288-554Ganirelix AcetateGanirelix Acetate
78206-138Ganirelix AcetateGanirelix Acetate

Trademark Results [Fyremadel]

Mark Image

Registration | Serial
Company
Trademark
Application Date
FYREMADEL
FYREMADEL
88221016 not registered Live/Pending
Ferring B.V.
2018-12-07

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.